US stock futures flounder amid tech weakness, Fed caution
On Thursday, Stifel analysts increased their price target on Rhythm Pharmaceuticals (NASDAQ:RYTM) shares, setting a new goal of $94.00, up from the previous target of $78.00, while reiterating a Buy rating on the stock. According to InvestingPro data, this aligns with the broader analyst consensus, as four analysts have recently revised their earnings estimates upward. The company, currently valued at $3.79 billion, has seen its stock deliver an impressive 68% return over the past year. The revision follows a comprehensive analysis of the company’s prospects, particularly regarding its obesity drug setmelanotide and its pipeline products.
The Stifel team delved into three critical aspects of Rhythm Pharmaceuticals’ future. Firstly, they assessed the potential market size for hypothalamic obesity (HO), concluding that it may be as significant as anticipated. Secondly, they examined the expected adoption rates of setmelanotide in treating HO, finding that the drug could meet or exceed the already high expectations. This optimism is supported by the company’s strong revenue growth of 48.88% and impressive gross profit margins of 89.62%, as reported by InvestingPro. Lastly, they considered the likelihood of success for the company’s pipeline drugs, bivamelagon and RM-718, in phase 2 trials.
The analysts emerged from their investigation with an increased confidence in the company’s prospects. They highlighted several upcoming clinical milestones in 2025 and the anticipated launch of the HO treatment in 2026 as positive catalysts for the stock. Stifel’s analysis suggests that the financial potential for treating HO could be substantial, with a market opportunity that might exceed $2 billion worldwide, viewing the $1 billion figure as a conservative estimate.
Moreover, the analysts expressed a cautiously optimistic outlook for the phase 2 data of bivamelagon and RM-718, which are expected in the third quarter and by the end of 2025, respectively. This anticipation of positive trial outcomes has contributed to the firm’s favorable view on Rhythm Pharmaceuticals’ shares.
Rhythm Pharmaceuticals is actively working on advancing its product pipeline, with setmelanotide at the forefront as a treatment for rare genetic disorders of obesity. The company is also exploring the efficacy of its other pipeline candidates in various stages of clinical development.
The updated price target reflects Stifel’s belief in the company’s ability to capitalize on these opportunities and deliver value to shareholders. With a healthy current ratio of 3.3 and moderate debt levels, the company maintains strong financial flexibility. As the market awaits further developments and data from Rhythm Pharmaceuticals, the company’s stock positioning appears strengthened by Stifel’s latest endorsement. For deeper insights into RYTM’s valuation and growth potential, investors can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports, which transform complex Wall Street data into actionable intelligence.
In other recent news, Rhythm Pharmaceuticals reported its Q1 2025 earnings, revealing a larger-than-expected loss per share and a decrease in revenue compared to forecasts. The company posted a GAAP EPS of -$0.81, falling short of the consensus estimate of -$0.6734, while revenue reached $37.72 million, missing the anticipated $40.7 million. Despite these results, Rhythm Pharmaceuticals continues to make progress in product development, including a planned Q3 filing for cetmelanotide. Analysts from various firms are closely monitoring the company’s advancements. Additionally, Rhythm Pharmaceuticals presented new data on its drug setmelanotide, showing potential efficacy in reducing BMI and hunger in patients with hypothalamic obesity. The findings, based on real-world use in France, demonstrated significant decreases in BMI among both adult and pediatric patients. The drug was generally well-tolerated, with no new safety concerns observed. Rhythm Pharmaceuticals remains on track to submit a supplemental New Drug Application to the FDA for setmelanotide in acquired hypothalamic obesity by the third quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.